Adverum Biotechnologies, Inc.

NasdaqCM ADVM

Adverum Biotechnologies, Inc. Price to Sales Ratio (P/S) on January 14, 2025

Adverum Biotechnologies, Inc. Price to Sales Ratio (P/S) is NA on January 14, 2025, a NA change year over year. Price to sales ratio compares the stock price to the sales per share; higher suggests positive sentiment for future revenue growth.

Adverum Biotechnologies, Inc. 52-week high Price to Sales Ratio (P/S) is NA on January 14, 2025, which is NA below the current Price to Sales Ratio (P/S).
Adverum Biotechnologies, Inc. 52-week low Price to Sales Ratio (P/S) is NA on January 14, 2025, which is NA below the current Price to Sales Ratio (P/S).
Adverum Biotechnologies, Inc. average Price to Sales Ratio (P/S) for the last 52 weeks is NA.

Key data

Date	Price to Sales Ratio (P/S)	Price to Book Ratio (P/B)	Dividend Yield	Free Cash Flow Yield

NasdaqCM: ADVM

Adverum Biotechnologies, Inc.

CEO	Dr. Laurent Fischer
IPO Date	July 31, 2014
Location	United States
Headquarters	800 Saginaw Drive
Employees	121
Sector	Health Care
Industries Biotechnology Clinical Trials Pharmaceuticals

Description

Adverum Biotechnologies, Inc., a clinical-stage gene therapy company, develops gene therapy product candidates to treat ocular and rare diseases. Its lead product candidate is ADVM-022, a single intravitreal injection gene therapy candidate used for the treatment of patients with chronic retinal, including wet age-related macular degeneration and diabetic macular edema. Adverum Biotechnologies, Inc. has license and collaboration agreements with University of California; Cornell University; GenSight; Lexeo; and Virovek. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016. Adverum Biotechnologies, Inc. was incorporated in 2006 and is headquartered in Redwood City, California.

Key trends

Past 5 years